Myriad and cephalon enter into companion diagnostic agreement Full Text
Myriad Genetics,

Myriad Genetics, Inc. announced that it has signed an agreement with Cephalon Inc., a subsidiary of Teva Pharmaceutical Industries Ltd Company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase I/II clinical study. We are extremely pleased to be working with Cephalon, one of the world's leading healthcare companies, on this exciting new clinical study," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "This collaboration is a further demonstration of Myriad's commitment to and leadership in the field of companion diagnostics."

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharma News

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharma News Articles

1 Toughest breast cancer may have met its match Johns Hopkins Medicine, December 11, 2014

2 Study: Investigational drug reduces high potassium levels in chronic kidney disease patients University of Maryland Medical Center News, November 25, 2014

3 Bacterial product could cure viral infections, scientists say Pennsylvania State University Health and Medicine News, November 21, 2014

4 Acetaminophen prescription combination drug products with more than 325 mg: FDA statement - recommendation to discontinue prescribing and dispensing Full Text Purdue Pharma, January 27, 2015    Free full text

5 New drug could make vaccines more effective in the elderly University of Oxford News, November 14, 2014

6 FDA approves carbidopa-levodopa extended-release capsules for Parkinson's disease Full Text American Pharmacists Association News, January 16, 2015    Free full text

7 Statin therapy and mortality from sepsis a meta-analysis of randomized trials American Journal of Medicine, January 6, 2015    Evidence Based Medicine    Review Article

8 UCLA research unlocks how melanoma resists new drug combination therapy UCLA Health System, January 16, 2015

9 FDA approves new upgraded Gardasil 9 The Lancet Oncology, January 8, 2015

10 Teva announces U.S. Supreme Court decision to reverse federal circuit courts judgment on copaxone 20 mg/ml case and remand for further review Full Text Teva Pharmaceutical Industries, January 23, 2015    Free full text

11 Efficacy comparison of duloxetine and SSRIs at doses approved in Japan Full Text Neuropsychiatric Disease and Treatment, January 16, 2015    Free full text

12 Biomarin announces approval of VIMIZIM (elosulfase alfa) in Japan for treatment of Morquio A Syndrome Full Text BioMarin, January 2, 2015    Free full text

13 Transcutaneous electrical nerve stimulation for chronic post-herpetic neuralgia International Journal of Dermatology, January 28, 2015    Clinical Article
Exclusive Author Commentary

14 Duke team brings life-saving function to ketchup packets Duke University Health & Medicine News, July 3, 2014

15 FDA approves anticlotting drug edoxaban Full Text American Pharmacists Association News, January 16, 2015    Free full text

16 Century-old drug reverses autism-like symptoms in fragile X mouse model UC San Diego Health System, January 16, 2015

17 Acetaminophen prescription combination drug products with more than 325 mg: FDA statement – recommendation to discontinue prescribing and dispensing Full Text Purdue Pharma, November 21, 2014    Free full text

18 FDA approves wider use of rapid flu test Full Text American Hospital Association News, January 16, 2015    Free full text

19 Regulatory update on three-part transaction with Novartis Full Text GlaxoSmithKline, January 29, 2015    Free full text

20 FDA approves Gazyva (Obinutuzumab) supplemental biologics license application with new data in previously untreated chronic lymphocytic leukemia Full Text Genentech, January 2, 2015    Free full text

Indexed Journals in Pharma News: U.S.Pharmacist, FDA Drug Alerts, Pharmiwebmore

Looking for a physician job? Let us help!

Register now for our free job placement service.
A career consultant will contact you soon.
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List